Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
National Institute on Drug Abuse, Bethesda 20892, MD, USA. aleshner@aaas.org
Alan I
AI
Leshner
D002047:Buprenorphine / Q000009:adverse effects / Q000627:therapeutic use*; D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D006801:Humans; D009270:Naloxone / Q000009:adverse effects / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009819:Office Visits / Q000639:trends; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000188:drug therapy*
D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine